- Home
- INAB vs BOLT Comparison
INAB vs BOLT Comparison
Compare INAB & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- BOLT
- Stock Information
- Founded
- INAB 2016
- BOLT 2015
- Country
- INAB United States
- BOLT United States
- Employees
- INAB N/A
- BOLT N/A
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- INAB Health Care
- BOLT Health Care
- Exchange
- INAB Nasdaq
- BOLT Nasdaq
- Market Cap
- INAB 18.8M
- BOLT 22.6M
- IPO Year
- INAB 2021
- BOLT 2021
- Fundamental
- Price
- INAB $0.27
- BOLT $0.49
- Analyst Decision
- INAB Strong Buy
- BOLT Hold
- Analyst Count
- INAB 3
- BOLT 5
- Target Price
- INAB $5.57
- BOLT $1.25
- AVG Volume (30 Days)
- INAB 14.2M
- BOLT 114.3K
- Earning Date
- INAB 03-13-2025
- BOLT 03-20-2025
- Dividend Yield
- INAB N/A
- BOLT N/A
- EPS Growth
- INAB N/A
- BOLT N/A
- EPS
- INAB N/A
- BOLT N/A
- Revenue
- INAB N/A
- BOLT $9,779,000.00
- Revenue This Year
- INAB N/A
- BOLT $9.87
- Revenue Next Year
- INAB N/A
- BOLT N/A
- P/E Ratio
- INAB N/A
- BOLT N/A
- Revenue Growth
- INAB N/A
- BOLT 35.86
- 52 Week Low
- INAB $0.22
- BOLT $0.46
- 52 Week High
- INAB $1.74
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- INAB 47.53
- BOLT 45.52
- Support Level
- INAB $0.25
- BOLT $0.48
- Resistance Level
- INAB $0.30
- BOLT $0.52
- Average True Range (ATR)
- INAB 0.04
- BOLT 0.03
- MACD
- INAB 0.00
- BOLT 0.00
- Stochastic Oscillator
- INAB 19.95
- BOLT 40.32
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.